Bacterially derived minicells loaded with siRNA reverse drug resistance in tumor xenografts.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chabner, B.A. & Roberts, T.G. Jr. Nat. Rev. Cancer 5, 65–72 (2005).
MacDiarmid, J.A. et al. Nat. Biotechnol. 27, 643–651 (2009).
Rubin, B.P. & Duensing, A. Lab. Invest. 86, 981–986 (2006).
Gottesman, M.M. et al. Nat. Rev. Cancer 2, 48–58 (2002).
Jain, R.K. Adv. Drug Deliv. Rev. 46, 149–168 (2001).
Peer, D. et al. Nat. Nanotechnol. 2, 751–760 (2007).
Langer, R. Nature 392, 5–10 (1998).
MacDiarmid, J.A. et al. Cell Cycle 6, 2099–2105 (2007).
MacDiarmid, J.A. et al. Cancer Cell 11, 431–445 (2007).
Whitehead, K.A. et al. Nat. Rev. Drug Discov. 8, 129–138 (2009).
Aouadi, M. et al. Nature 458, 1180–1184 (2009).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Karagiannis, E., Anderson, D. Minicells overcome tumor drug-resistance. Nat Biotechnol 27, 620–621 (2009). https://doi.org/10.1038/nbt0709-620
Issue Date:
DOI: https://doi.org/10.1038/nbt0709-620